Kvd001 Emerging Insight And Market Forecast

“KVD001- Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Diabetic Macular Edema in 7 Major Markets. A detailed picture of the KVD001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview

KVD001 is a small molecule plasma kallikrein inhibitor administered by intravitreal injection. The Phase 2 trial consisted of 129 patients who had previously been treated with anti-VEGF therapy, and still had significant edema and reduced visual acuity. The sham-controlled, double-masked clinical trial evaluated two dose levels of KVD001, 3μg and 6μg. Four intravitreal injections or sham were administered over three months with a three month follow up period. The study was conducted at 38 sites in the United States.

Scope of the report

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around KVD001.
  • The report contains forecasted sales for KVD001 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for Diabetic Macular Edema.
  • The report also features the SWOT analysis with analyst insights and key findings of KVD001.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

KVD001 Analytical Perspective by DelveInsight

  • In-depth KVD001 Market Assessment

This report provides a detailed market assessment of KVD001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.


  • KVD001 Clinical Assessment

The report provides the clinical trials information of KVD001 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights  

  • In the coming years, the market scenario for Diabetic Macular Edema is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
  • The companies and academics are working to assess challenges and seek opportunities that could influence KVD001 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Diabetic Macular Edema are giving market competition to KVD001 and launch of late-stage emerging therapies in the near future will significantly impact the market.  
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of KVD001.
  • Our in-depth analysis of the forecasted sales data of KVD001 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the KVD001. 

Key Questions

  • Which company is developing KVD001 along with the phase of the clinical study?
  • What is the technology utilized in the development of KVD001?
  • What is the product type, route of administration and mechanism of action of KVD001?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the KVD001 development?
  • What are the key designations that have been granted to KVD001?
  • What is the forecasted market scenario of KVD001?
  • What is the history of KVD001 and what is its future?
  • What is the forecasted sales of KVD001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?  
  • What are the other emerging products available and how these are giving competition to KVD001?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

 

1. Drug Overview

1.1. Product Detail

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4. Research and development activity

1.4.1. Clinical Development

1.4.2. Safety and Efficacy

1.5. Other Development Activities

2. Market Assesment

2.1. 7MM Market Analysis

2.2. The United States Market

2.3. Germany Market

2.4. France Market

2.5. Italy Market

2.6. Spain Market

2.7. United Kingdom Market

2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Table

Table 1 KVD001, Description

Table 2 KVD001, Clinical Trial Description

Table 3 KVD001, 7MM Market Size from 2020 to 2030 (in Million USD)

Table 4 Market Competitors

Table 5 Other Emerging Therapies

List of Figures

Figure 1 The Development Timeline of KVD001

Figure 2 Patent Details, KVD001

Figure 3 KVD001, 7MM Market Size from 2020 to 2030 (in Million USD)

Figure 4 KVD001, US Market Size from 2020 to 2030 (in Millions USD)

Figure 5 KVD001, EU5 Market Size from 2020 to 2030 (in Millions USD)

Figure 6 KVD001, Japan Market Size from 2020 to 2030 (in Millions USD)

  • Tags:
  • "KVD001
  • KVD001 Marketed Drugs Overview
  • KVD001 Market Assessment
  • KVD001 API Manufacturers/ Active P...
  • KVD001 US DMF
  • KVD001 US Drug Master Files
  • KVD001 Active Substance Master Fil...
  • KVD001 Generic players
  • KVD001 Patent Expiration
  • KVD001 Patent Exclusivity
  • KVD001 API Manufacturers
  • KVD001 Global Forecasted Sales Fig...
  • KVD001 API Route of Synthesis
  • KVD001 Market sales
  • KVD001 SWOT Analysis
  • KVD001 Pipeline "

Forward to Friend

Need A Quote